Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2015 - 2026)

Arbutus Biopharma has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $11000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $11000.0, down 96.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $33000.0 (down 96.77% YoY), and the FY2025 annual result was $400000.0, down 71.01% from the prior year.
• Depreciation & Amortization (CF) came in at $11000.0 for Q1 2026 at Arbutus Biopharma, roughly flat from $11000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $394000.0 in Q1 2022 to a low of $11000.0 in Q2 2025.
• The 5-year median for Depreciation & Amortization (CF) is $342000.0 (2023), against an average of $275000.0.
• Across the five-year window, Depreciation & Amortization (CF) increased 7.58% in 2023 and plunged 96.91% in 2025, its largest moves.
• Arbutus Biopharma's Depreciation & Amortization (CF) stood at $343000.0 in 2022, then advanced by 7.58% to $369000.0 in 2023, then decreased by 8.94% to $336000.0 in 2024, then plunged by 96.73% to $11000.0 in 2025, then changed by 0.0% to $11000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $11000.0 (Q1 2026), $11000.0 (Q3 2025), and $11000.0 (Q2 2025), per Business Quant data.